Budget Impact Analysis of a Fixed-Dose Combination of Fluticasone Propionate and Formoterol Fumarate (FP/FORM) in a Pressurized Metered-Dose Inhaler (pMDI) for Asthma.

CONCLUSIONS: The comparable efficacy and lower acquisition costs of FP/FORM compared with FP/SAL make it a cost-saving option for the UK NHS for the treatment of asthma patients requiring combination maintenance therapy using a pMDI.
PMID: 24194361 [PubMed - as supplied by publisher]

Source: Advances in Therapy - November 6, 2013 Category: Drugs & Pharmacology Authors: Dunlop W, Heron L, Fox G, Greaney M Tags: Adv Ther Source Type: research